Statistical heterogeneity between included studies was not detected ( chi(2 ) = 1.68 , P = 0.43 , I(2 ) = 0 % ) , although significant clinical differences were found in terms of study design , patient population s , statins use and dosage and AF-monitoring capabilities .
Statins may represent a novel treatment strategy to prevent the occurrence of AF in patients with PM , especially for those who had a PM implanted due to sinus node dysfunction .
Patients with permanent pacemakers ( PM ) are at high risk of developing atrial fibrillation ( AF ) .
Minimal ventricular pacing modalities have been demonstrated to reduce AF in such patients , although they are not suitable for patients with advanced atrioventricular conduction disease .
Recent evidence s suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ( i.e. statins ) may represent a new strategy to prevent AF in patients at risk .
In this article , we sought to review data regarding the effectiveness of statin therapy in preventing AF patients with a PM .
Randomized pilot study of a new atrial-based minimal ventricular pacing mode in dual-chamber implantable cardioverter-defibrillators.
OBJECTIVE We hypothesized that a new minimal ventricular pacing mode ( MVP ) that provides AAI/R pacing with ventricular monitoring and back-up DDD/R pacing as needed during AV block ( AVB ) would significantly reduce cumulative percent ventricular pacing compared to DDD/R. BACKGROUND Conventional DDD/R mode often results in high cumulative percent ventricular pacing that may adversely affect ventricular function and increase risk of heart failure and atrial fibrillation . METHODS MVP was made operational in 30 patients with DDD/R implantable cardioverter-defibrillators ( ICDs ) and no history of AVB . Patients were r and omized to one week each in DDD/R and MVP . Holter monitor recordings ( ECG , intracardiac electrograms , and event markers ) and device diagnostics were analyzed for cumulative % atrial paced ( Cum%AP ) , cumulative percent ventricular pacing , and frequency and duration of DDD/R pacing back-up . Diaries were used to report symptoms . RESULTS Age of the study population was 61 years + /- 12 years and 83 % were male . Baseline PR interval was 204 ms + /- 32 ms and programmed AV intervals ( DDD/R ) were 200 ms + /- 50 ms (paced)/167 ms + /- 54 ms ( sensed ) . Cum%AP was similar between MVP and DDD/R ( 47.9 + /- 37 vs 46.3 + /- 36 ) . Cumulative percent ventricular pacing was significantly lower in MVP vs DDD/R ( 3.79 + /- 16.3 vs 80.6 + /- 33.8 , P < .0001 ) . Back-up DDD/R pacing during MVP operation due to transient AVB occurred in 10 % of patients ( 9.3 + /- 7.4 [ range 1 - 15 ] episodes/patient-day , duration 39.7 minutes + /- 156 minutes ) . Fifteen percent of AV intervals during MVP operation exceeded 300 ms . No significant symptoms were reported during MVP operation . CONCLUSIONS MVP dramatically reduced cumulative percent ventricular pacing compared to DDD/R while maintaining AV synchrony and providing sensor-modulated atrial pacing support . Intermittent oscillations between MVP and DDD/R during transient AV block appeared safe and well tolerated
Statistical heterogeneity between included studies was not detected ( chi(2 ) = 1.68 , P = 0.43 , I(2 ) = 0 % ) , although significant clinical differences were found in terms of study design , patient population s , statins use and dosage and AF-monitoring capabilities .
Statins may represent a novel treatment strategy to prevent the occurrence of AF in patients with PM , especially for those who had a PM implanted due to sinus node dysfunction .
Patients with permanent pacemakers ( PM ) are at high risk of developing atrial fibrillation ( AF ) .
Minimal ventricular pacing modalities have been demonstrated to reduce AF in such patients , although they are not suitable for patients with advanced atrioventricular conduction disease .
Recent evidence s suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ( i.e. statins ) may represent a new strategy to prevent AF in patients at risk .
In this article , we sought to review data regarding the effectiveness of statin therapy in preventing AF patients with a PM .